No Data
No Data
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $21
Sector Update: Health Care Stocks Slipping in Afternoon Trading
Update: Market Chatter: Teva Pharmaceuticals Faces FTC Probe on Patent Listings
Teva Focus of FTC Investigation Over Inhaler Patents
FTC Opens Investigation Into Teva Pharmaceuticals, Washington Post Reports
Vanda Will Request Relief From Court That Includes Order Requiring Defendants to Discontinue Marketing Generic Versions of HETLIOZ >VNDA
loading...